Identifying the optimal schedule for a multi-pathogen combination vaccine for diarrheal disease.

Authors

Shane A Conyers, Aniruddha Deshpande, Avnika B Amin, Ritesh Sivakumar, Elizabeth Rogawski McQuade, Ben Lopman

Published in

Epidemics. Volume 56. Pages 100936. Jul 24, 2026. Epub Jul 24, 2026.

Abstract

Diarrheal disease causes 1·7 billion cases and 340,000 childhood deaths annually, with rotavirus still bearing the highest death burden despite vaccine availability. A combination vaccine targeting multiple enteropathogens could expand protection while reducing injections, visits, and costs. However, optimizing administration schedules is complex due to differences in pathogen transmissibility, immunity, and age-specific burden.
We developed an age-structured, compartmental model with pathogen-specific parameters from eight LMIC sites. Two-dose viral (rotavirus, norovirus, adenovirus 40/41) and bacterial (Shigella, ETEC) vaccines were modeled across five age schedules and variable vaccine coverage. We examined two scenarios where (a) VE was the same at all ages of administration (age-uniform) and (b) VE was lower in early childhood (age-attenuated). Outcomes included annual cases and deaths in children under five.
With age-uniform VE, the earliest schedules produced the greatest reductions in burden, with birth/6 weeks yielding the largest mean reduction in deaths (56%, 95% UI: 41-74%) and 6/10 weeks producing similar reductions (55%, 95% UI: 39-74%). Case reductions were also comparable between schedules, with birth/6 weeks reducing cases by 34% (95% UI: 15-69%) and 6/10 weeks by 35% (95% UI: 15-70%). With age-attenuated VE, 6/10 weeks was optimal, reducing cases by 21% (95% UI: 7-49%) and deaths by 42% (95% UI: 29-58%).
All schedules reduced diarrheal disease burden. Under age-uniform VE, birth/6 weeks conferred the greatest reduction in deaths, although impacts were similar to 6/10 weeks. Under age-attenuated VE, the 6/10 weeks schedule performed best.

PMID:
42520749
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.